ScholarLens Back to search
2012•Journal of Vector Borne DiseasesOpen access

Bradycardia in a patient with crimean-congo hemorrhagic fever related to ribavirin treatment

Gökhan Metan, Burcu Uysal

Open full text 9 citations

Abstract

Crimean-Congo hemorrhagic fever (CCHF) has been reported from more than 30 countries around the world. Ribavirin is the only drug which has in vitro effect on CCHF virus. Although there is a debate on the clinical benefit of ribavirin, some experts from the endemic areas strongly recommend ribavirin in patients with CCHF based on in vitro activity and rare adverse events with shortterm use1. Here, we report bradycardia in a patient with CCHF related to high dose ribavirin administration.

About this research paper

What this paper is about

Crimean-Congo hemorrhagic fever (CCHF) has been reported from more than 30 countries around the world. Ribavirin is the only drug which has in vitro effect on CCHF virus. Although there is a debate on the clinical benefit of ribavirin, some experts from the endemic areas strongly recommend ribavirin in patients with CCHF based on in vitro activity and rare adverse events with shortterm use1. Here, we report bradycardia in a patient with CCHF related to high dose ribavirin administration.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Crimean-Congo hemorrhagic fever (CCHF) has been reported from more than 30 countries around the world. Ribavirin is the only drug which has in vitro effect on CCHF virus. Although there is a debate on the clinical benefit of ribavirin, some experts from the endemic areas strongly recommend ribavirin in patients with CCHF based on in vitro activity and rare adverse events with shortterm use1. Here, we report bradycardia in a patient with CCHF related to high dose ribavirin administration.

Key concepts: Ribavirin, Crimean–Congo hemorrhagic fever, Medicine, Bradycardia, Adverse effect, Pharmacology, Intensive care medicine, Traditional medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Bradycardia in a patient with crimean-congo hemorrhagic fever related to ribavirin treatment — Research Paper | ScholarLens